Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.
Melanoma|Hepatocellular Carcinoma (HCC)|Renal Cell Carcinoma (RCC)|Microsatellite Instability - High (MSI-H)|Mismatch Repair Deficient (dMMR)|Colorectal Carcinoma (CRC)
DRUG: INCB 99280 with Ipilimumab
Occurence of DLTs, 2 Years|Incidence of TEAEs, Assessed by physical examinations, changes in vital signs and ECGs, and analysis of clinical laboratory samples., 2 Years|Incidence of TEAEs leading to dose interruption, dose reduction, or discontinuation of either of the study drugs, 2 Years
Concentration of INCB099280 in plasma, 2 Years|Objective response, Defined as having a best overall response of complete response or partial response by investigator assessment per RECIST v1.1., 2 Years|Disease control, Defined as having a best overall response of complete response or partial response, or stable disease of â‰¥ 15 weeks after initiation of study treatment, by investigator assessment per RECIST v1.1., 2 Years|Duration of Response, Defined as the time from the earliest date of CR or PR until the earliest date of disease progression (by investigator assessment per RECIST v1.1) or death due to any cause if occurring sooner than progression., 2 Years
The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.